Health CanadaGeneral Alert
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
Published: February 3, 2022Recall ID: 63879Category: generalCountry: Canada
Safety AlertHealth Canada
Canada
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
Recalling Firm: Marketed health products
Reason for Recall / Hazard
New safety information - Product safety
Product Description & Identification
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
Affected Products
BEOVU (brolucizumab)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 63879 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/beovu-brolucizumab-risk-intraocular-inflammation-retinal-vasculitis-andor-retinal |
| Issue | New safety information - Product safety |
| Title | BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion |
| Product | BEOVU (brolucizumab) |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2022-02-03 |
| Organization | Marketed health products |
Check Other Products In Your Household
Free Safety ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmMarketed health products
Recall Hazard Severity
Official Agency AlertCaution (Class III)
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: Marketed health products - BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion Check if your household is affected: https://therecallfile.com/recalls/beovu-brolucizumab-risk-of-intraocular-inflammation-retinal-vasculitis/CANADA-63879
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Support The Recall File
Help keep official recall alerts free, accessible, and fast for everyone.
Spread the WordBEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion